Gastric Cancer Drugs Market by Molecule Type (Biologics, Small Molecules), Lines of Chemotherapy (First-line Chemotherapy, Second-line Chemotherapy), Route of Administration - Global Forecast 2024-2030

Gastric Cancer Drugs Market by Molecule Type (Biologics, Small Molecules), Lines of Chemotherapy (First-line Chemotherapy, Second-line Chemotherapy), Route of Administration - Global Forecast 2024-2030


The Gastric Cancer Drugs Market size was estimated at USD 3.83 billion in 2023 and expected to reach USD 4.06 billion in 2024, at a CAGR 6.14% to reach USD 5.81 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gastric Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gastric Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gastric Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., ASLAN Pharmaceuticals Pte Ltd, AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., SELLAS Life Sciences Group, Inc., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage



This research report categorizes the Gastric Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Molecule Type
Biologics
Small Molecules
Lines of Chemotherapy
First-line Chemotherapy
Second-line Chemotherapy
Route of Administration
Oral
Parenteral
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gastric Cancer Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gastric Cancer Drugs Market?
3. What are the technology trends and regulatory frameworks in the Gastric Cancer Drugs Market?
4. What is the market share of the leading vendors in the Gastric Cancer Drugs Market?
5. Which modes and strategic moves are suitable for entering the Gastric Cancer Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Gastric Cancer Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
5.1.1.2. Introduction of novel therapies for metastatic stomach cancer
5.1.1.3. Increase in awareness about the symptoms and causes of gastric cancer
5.1.2. Restraints
5.1.2.1. Stringent regulations and policies for approval of the drugs
5.1.3. Opportunities
5.1.3.1. Accelerating research and development activities in the drugs for gastic cancer
5.1.3.2. Rapid adoption of biosimilars in oncology
5.1.4. Challenges
5.1.4.1. Availability of the counterfeit drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Gastric Cancer Drugs Market, by Molecule Type
6.1. Introduction
6.2. Biologics
6.3. Small Molecules
7. Gastric Cancer Drugs Market, by Lines of Chemotherapy
7.1. Introduction
7.2. First-line Chemotherapy
7.3. Second-line Chemotherapy
8. Gastric Cancer Drugs Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Americas Gastric Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Gastric Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Gastric Cancer Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amgen Inc.
13.1.2. ASLAN Pharmaceuticals Pte Ltd
13.1.3. AstraZeneca PLC
13.1.4. Bayer AG
13.1.5. Bristol Myers Squibb Company
13.1.6. Eli Lilly and Company
13.1.7. F. Hoffmann-La Roche AG
13.1.8. GlaxoSmithKline PLC
13.1.9. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
13.1.10. Merck & Co., Inc.
13.1.11. Novartis AG
13.1.12. Pfizer Inc.
13.1.13. SELLAS Life Sciences Group, Inc.
13.1.14. Taiho Pharmaceutical Co., Ltd.
13.1.15. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. GASTRIC CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GASTRIC CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GASTRIC CANCER DRUGS MARKET DYNAMICS
FIGURE 7. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
FIGURE 8. GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2030 (%)
FIGURE 10. GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings